Skip to main content
Erschienen in: Current Bladder Dysfunction Reports 4/2023

02.10.2023

Role of Onabotulinum Toxin-A Injection in the Management of Pain and Sexual Dysfunction in Women with BPS/IC

verfasst von: Murat Can Karaburun, Ömer Gülpınar

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

In this review, we aimed to summarize the effects of BoNT-A injections on pain and sexual dysfunction in women with BPS/IC in the light of current literature.

Recent Findings

In recent years, randomized controlled studies have provided evidence for the positive effects of intravesical BoNT-A treatment on pain and quality of life scores in patients with BPS/IC. Trigonal injections have demonstrated similar efficacy and safety to those administered to the bladder body. Furthermore, noninvasive alternatives such as low-energy shock wave plus intravesical instillation, hydrogel-based instillation, and liposome-encapsulated BoNT-A instillations have been explored for patients with BPS/IC. The studies examining the impact of BoNT-A on sexual functions are limited. Only one published study has shown improvement in sexual functions with intravesical BoNT-A.

Summary

Intravesical BoNT-A treatment in BPS/IC patients is an effective and safe method recommended by the guidelines. In the light of current literature, this treatment also provides an improvement in sexual functions.
Literatur
1.
Zurück zum Zitat Engeler D, Baranowski A, Borovicka J. EAU guidelines on chronic pelvic pain. Copenhagen: EAU Guidelines. in EAU Annual Congress; 2018. Engeler D, Baranowski A, Borovicka J. EAU guidelines on chronic pelvic pain. Copenhagen: EAU Guidelines. in EAU Annual Congress; 2018.
2.
Zurück zum Zitat Hanno PM, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53.CrossRefPubMed Hanno PM, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53.CrossRefPubMed
3.
Zurück zum Zitat Engeler DS, et al. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol. 2013;64(3):431–9.CrossRefPubMed Engeler DS, et al. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol. 2013;64(3):431–9.CrossRefPubMed
4.
Zurück zum Zitat Bogart LM, et al. Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis. Urology. 2011;77(3):576–80.CrossRefPubMed Bogart LM, et al. Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis. Urology. 2011;77(3):576–80.CrossRefPubMed
5.
Zurück zum Zitat Giannantoni A, et al. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol. 2008;179(3):1031–4.CrossRefPubMed Giannantoni A, et al. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol. 2008;179(3):1031–4.CrossRefPubMed
6.
Zurück zum Zitat Sacco E, et al. Bladder pain syndrome associated with highest impact on sexual function among women with lower urinary tract symptoms. Int J Gynaecol Obstet. 2012;117(2):168–72.CrossRefPubMed Sacco E, et al. Bladder pain syndrome associated with highest impact on sexual function among women with lower urinary tract symptoms. Int J Gynaecol Obstet. 2012;117(2):168–72.CrossRefPubMed
7.
Zurück zum Zitat Okui N, Okui M, Gambacciani M. Examining vaginal and vulvar health and sexual dysfunction in patients with interstitial cystitis (UNICORN-1 study). Int Urogynecol J. 2022;33(9):2493–9.CrossRefPubMed Okui N, Okui M, Gambacciani M. Examining vaginal and vulvar health and sexual dysfunction in patients with interstitial cystitis (UNICORN-1 study). Int Urogynecol J. 2022;33(9):2493–9.CrossRefPubMed
8.
Zurück zum Zitat Gupta P, et al. A multidisciplinary approach to the evaluation and management of interstitial cystitis/bladder pain syndrome: an ideal model of care. Transl Androl Urol. 2015;4(6):611–9.PubMedPubMedCentral Gupta P, et al. A multidisciplinary approach to the evaluation and management of interstitial cystitis/bladder pain syndrome: an ideal model of care. Transl Androl Urol. 2015;4(6):611–9.PubMedPubMedCentral
9.
Zurück zum Zitat Peters KM, et al. Sexual function and sexual distress in women with interstitial cystitis: a case-control study. Urology. 2007;70(3):543–7.CrossRefPubMed Peters KM, et al. Sexual function and sexual distress in women with interstitial cystitis: a case-control study. Urology. 2007;70(3):543–7.CrossRefPubMed
10.
Zurück zum Zitat Carrico DJ, Sherer KL, Peters KM. The relationship of interstitial cystitis/painful bladder syndrome to vulvodynia. Urol Nurs. 2009;29(4):233–8.PubMed Carrico DJ, Sherer KL, Peters KM. The relationship of interstitial cystitis/painful bladder syndrome to vulvodynia. Urol Nurs. 2009;29(4):233–8.PubMed
11.
Zurück zum Zitat Dykstra DD, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22.CrossRefPubMed Dykstra DD, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22.CrossRefPubMed
12.
Zurück zum Zitat Schurch B, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.CrossRefPubMed Schurch B, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7.CrossRefPubMed
13.
Zurück zum Zitat Schulte-Baukloh H, et al. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology. 2005;66(1):82–7.CrossRefPubMed Schulte-Baukloh H, et al. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology. 2005;66(1):82–7.CrossRefPubMed
14.
Zurück zum Zitat Smith CP, et al. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5 (discussion 875).CrossRefPubMed Smith CP, et al. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–5 (discussion 875).CrossRefPubMed
15.
Zurück zum Zitat Zhang W, et al. Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis. Int Urogynecol J. 2017;28(4):515–25.CrossRefPubMed Zhang W, et al. Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis. Int Urogynecol J. 2017;28(4):515–25.CrossRefPubMed
16.
Zurück zum Zitat Brown EA, Schütz SG, Simpson DM. Botulinum toxin for neuropathic pain and spasticity: an overview. Pain Manag. 2014;4(2):129–51.CrossRefPubMed Brown EA, Schütz SG, Simpson DM. Botulinum toxin for neuropathic pain and spasticity: an overview. Pain Manag. 2014;4(2):129–51.CrossRefPubMed
17.
Zurück zum Zitat Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel). 2017;9(9):260.CrossRefPubMed Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel). 2017;9(9):260.CrossRefPubMed
18.
Zurück zum Zitat Lagueny A, Burbaud P. Mechanism of action, clinical indication and results of treatment of botulinum toxin. Neurophysiol Clin. 1996;26(4):216–26.CrossRefPubMed Lagueny A, Burbaud P. Mechanism of action, clinical indication and results of treatment of botulinum toxin. Neurophysiol Clin. 1996;26(4):216–26.CrossRefPubMed
19.
Zurück zum Zitat Chen JL, Kuo HC. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol. 2020;61(Suppl 1):S33-s42.CrossRefPubMed Chen JL, Kuo HC. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis. Investig Clin Urol. 2020;61(Suppl 1):S33-s42.CrossRefPubMed
20.
Zurück zum Zitat Lucioni A, et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101(3):366–70.CrossRefPubMed Lucioni A, et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101(3):366–70.CrossRefPubMed
21.
Zurück zum Zitat Yiangou Y, et al. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int. 2001;87(9):774–9.CrossRefPubMed Yiangou Y, et al. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int. 2001;87(9):774–9.CrossRefPubMed
22.
Zurück zum Zitat Guo BL, et al. A closer look to botulinum neurotoxin type A-induced analgesia. Toxicon. 2013;71:134–9.CrossRefPubMed Guo BL, et al. A closer look to botulinum neurotoxin type A-induced analgesia. Toxicon. 2013;71:134–9.CrossRefPubMed
23.
Zurück zum Zitat Chiu B, et al. Botulinum toxin A for bladder pain syndrome/interstitial cystitis. Toxins (Basel). 2016;8(7):201.CrossRefPubMed Chiu B, et al. Botulinum toxin A for bladder pain syndrome/interstitial cystitis. Toxins (Basel). 2016;8(7):201.CrossRefPubMed
24.
Zurück zum Zitat Sengupta JN. Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol. 2009;194:31–74.CrossRef Sengupta JN. Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol. 2009;194:31–74.CrossRef
25.
Zurück zum Zitat Jhang JF. Using botulinum toxin A for treatment of interstitial cystitis/bladder pain syndrome-possible pathomechanisms and practical issues. Toxins (Basel). 2019;11(11):641.CrossRefPubMed Jhang JF. Using botulinum toxin A for treatment of interstitial cystitis/bladder pain syndrome-possible pathomechanisms and practical issues. Toxins (Basel). 2019;11(11):641.CrossRefPubMed
26.
Zurück zum Zitat Jhang JF, Kuo HC. Novel applications of onabotulinum toxin A in lower urinary tract dysfunction. Toxins (Basel). 2018;10(7):260.CrossRefPubMed Jhang JF, Kuo HC. Novel applications of onabotulinum toxin A in lower urinary tract dysfunction. Toxins (Basel). 2018;10(7):260.CrossRefPubMed
27.
Zurück zum Zitat Yosef A, et al. Multifactorial contributors to the severity of chronic pelvic pain in women. Am J Obstet Gynecol. 2016;215(6):760.e1-760.e14.CrossRefPubMed Yosef A, et al. Multifactorial contributors to the severity of chronic pelvic pain in women. Am J Obstet Gynecol. 2016;215(6):760.e1-760.e14.CrossRefPubMed
29.
Zurück zum Zitat •• Jiang YH, et al. Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinum toxin A injection in the treatment of interstitial cystitis refractory to conventional treatment-a prospective, randomized, clinical trial. Neurourol Urodyn. 2018;37(4):1467–73. This trial compared the injection locations.CrossRefPubMed •• Jiang YH, et al. Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinum toxin A injection in the treatment of interstitial cystitis refractory to conventional treatment-a prospective, randomized, clinical trial. Neurourol Urodyn. 2018;37(4):1467–73. This trial compared the injection locations.CrossRefPubMed
30.
Zurück zum Zitat •• Evans RJ, et al. Injection location does not impact botulinum toxin A efficacy in interstitial cystitis/bladder pain syndrome patients. Can J Urol. 2020;27(1):10125–9. This trial compared the injection locations.PubMed •• Evans RJ, et al. Injection location does not impact botulinum toxin A efficacy in interstitial cystitis/bladder pain syndrome patients. Can J Urol. 2020;27(1):10125–9. This trial compared the injection locations.PubMed
31.
Zurück zum Zitat •• Pinto RA, et al. Intratrigonal onabotulinum toxin A improves bladder symptoms and quality of life in patients with bladder pain syndrome/interstitial cystitis: a pilot, single center, randomized, double-blind, placebo controlled trial. J Urol. 2018;199(4):998–1003. This trial showed the efficacy of trigonal injections.CrossRefPubMed •• Pinto RA, et al. Intratrigonal onabotulinum toxin A improves bladder symptoms and quality of life in patients with bladder pain syndrome/interstitial cystitis: a pilot, single center, randomized, double-blind, placebo controlled trial. J Urol. 2018;199(4):998–1003. This trial showed the efficacy of trigonal injections.CrossRefPubMed
32.
Zurück zum Zitat Jhang JF, Kuo HC. Novel applications of non-invasive intravesical botulinum toxin a delivery in the treatment of functional bladder disorders. Toxins (Basel). 2021;13(5):359.CrossRefPubMed Jhang JF, Kuo HC. Novel applications of non-invasive intravesical botulinum toxin a delivery in the treatment of functional bladder disorders. Toxins (Basel). 2021;13(5):359.CrossRefPubMed
33.
Zurück zum Zitat Chuang YC, Kuo HC. A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinum toxin A for interstitial cystitis/bladder pain syndrome. J Urol. 2017;198(2):376–82.CrossRefPubMed Chuang YC, Kuo HC. A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinum toxin A for interstitial cystitis/bladder pain syndrome. J Urol. 2017;198(2):376–82.CrossRefPubMed
34.
Zurück zum Zitat Rappaport YH, et al. Safety and feasibility of intravesical instillation of botulinum toxin-A in hydrogel-based slow-release delivery system in patients with interstitial cystitis-bladder pain syndrome: a pilot study. Urology. 2018;114:60–5.CrossRefPubMed Rappaport YH, et al. Safety and feasibility of intravesical instillation of botulinum toxin-A in hydrogel-based slow-release delivery system in patients with interstitial cystitis-bladder pain syndrome: a pilot study. Urology. 2018;114:60–5.CrossRefPubMed
36.
Zurück zum Zitat Jiang YH, et al. Low-energy shock wave plus intravesical instillation of botulinum toxin A for interstitial cystitis/bladder pain syndrome: pathophysiology and preliminary result of a novel minimally invasive treatment. Biomedicines. 2022;10(2):396.CrossRefPubMedPubMedCentral Jiang YH, et al. Low-energy shock wave plus intravesical instillation of botulinum toxin A for interstitial cystitis/bladder pain syndrome: pathophysiology and preliminary result of a novel minimally invasive treatment. Biomedicines. 2022;10(2):396.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat •• Chen A, Shahiyan RH, Anger JT. Interstitial cystitis/bladder pain syndrome treatment: a systematic review of sexual health outcomes. Sex Med Rev. 2022;10(1):71–6. This review focused on the sexual health outcomes of Interstitial cystitis/Bladder pain syndrome.CrossRefPubMed •• Chen A, Shahiyan RH, Anger JT. Interstitial cystitis/bladder pain syndrome treatment: a systematic review of sexual health outcomes. Sex Med Rev. 2022;10(1):71–6. This review focused on the sexual health outcomes of Interstitial cystitis/Bladder pain syndrome.CrossRefPubMed
38.
Zurück zum Zitat •• Topcuoglu M, et al. Sexual dysfunction in women with interstitial cystitis/bladder pain syndrome: do onabotulinum toxin-A injections improve sexual function? Neurourol Urodyn. 2023;42(3):607–14. This is the first study investigating BoNT-A effects on sexual functions in patients with IC/BPS.CrossRefPubMed •• Topcuoglu M, et al. Sexual dysfunction in women with interstitial cystitis/bladder pain syndrome: do onabotulinum toxin-A injections improve sexual function? Neurourol Urodyn. 2023;42(3):607–14. This is the first study investigating BoNT-A effects on sexual functions in patients with IC/BPS.CrossRefPubMed
39.
Zurück zum Zitat Balzarro M, et al. Onabotulinum toxin A detrusor injection improves female sexual function in women with overactive bladder wet syndrome. Eur J Obstet Gynecol Reprod Biol. 2018;225:228–31.CrossRefPubMed Balzarro M, et al. Onabotulinum toxin A detrusor injection improves female sexual function in women with overactive bladder wet syndrome. Eur J Obstet Gynecol Reprod Biol. 2018;225:228–31.CrossRefPubMed
40.
Zurück zum Zitat Shawer S, et al. Impact of intravesical onabotulinum toxin A (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis. Int Urogynecol J. 2022;33(2):235–43.PubMed Shawer S, et al. Impact of intravesical onabotulinum toxin A (Botox) on sexual function in patients with overactive bladder syndrome: a systematic review and meta-analysis. Int Urogynecol J. 2022;33(2):235–43.PubMed
Metadaten
Titel
Role of Onabotulinum Toxin-A Injection in the Management of Pain and Sexual Dysfunction in Women with BPS/IC
verfasst von
Murat Can Karaburun
Ömer Gülpınar
Publikationsdatum
02.10.2023
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 4/2023
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-023-00715-5

Weitere Artikel der Ausgabe 4/2023

Current Bladder Dysfunction Reports 4/2023 Zur Ausgabe

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.